Defining target antigens in linear IgA disease using skin from subjects with inherited epidermolysis bullosa as a substrate for indirect immunofluorescence microscopy

British Journal of Dermatology

Volumn 141, Issue 3, 1999, Pages 475-480

  Harman, K E ^a   Bhogal, B S ^a   Eady, R A J ^a   Mcgrath, J A ^a   Black, M M ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antigen identification; BP180; Epidermolysis bullosa; Indirect immunofluorescence microscopy; Laminin 5; Linear IgA disease; Type VII collagen

Indexed keywords

COLLAGEN TYPE 7; IMMUNOGLOBULIN A; KALININ;

ADULT; ANTIGEN DETECTION; ANTIGEN RETRIEVAL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPIDERMOLYSIS BULLOSA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGLOBULIN DEPOSITION; PRIORITY JOURNAL; SKIN;

ADULT; ANTIGENS; AUTOANTIBODIES; AUTOANTIGENS; BASEMENT MEMBRANE; CARRIER PROTEINS; CELL ADHESION MOLECULES; COLLAGEN; CYTOSKELETAL PROTEINS; EPIDERMOLYSIS BULLOSA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOGLOBULIN A; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NERVE TISSUE PROTEINS; NON-FIBRILLAR COLLAGENS; SKIN; SKIN DISEASES, VESICULOBULLOUS;

EID: 0032852153     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.03041.x     Document Type: Article

References (25)

1. Bhogal BS, Black MM. Diagnosis, diagnostic and research techniques. In: Management of Blistering Diseases (Wojnarowska F. Briggaman RA, eds), 1st edn. London: Chapman & Hall Ltd, 1990: 15-34.
2. Amagai M, Hashimoto T. Shimizu N et al. Absorption of pathogenic autoantibodies by the extracellular domain in pemphigus vulgaris antigen (Dsg 3) produced by baculovirus. J Clin Invest 1994; 94: 59-67.
3. Amagai M, Hashimoto T, Green KJ et al. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 1995; 104: 895-901.
4. Liu Z, Diaz LA, Troy JL et al. A passive transfer model of the organspecific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen. BP180. J Clin Invest 1993; 92: 2480-8.
5. Lazarova Z, Yee C, Darling T et al. Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 1996; 98: 1509-18.
6. McGrath JA, Eady RAJ. The role of immunohistochemistry in the diagnosis of the non-lethal forms of junctional epidermolysis bullosa. J Dermatol Sci 1997; 14: 68-75.
7. Mellerio JE, Denyer JE, Atherton DJ et al. Prognostic implications of determining the 180-kDa bullous pemphigoid antigen (BPAC2) gene/protein pathology in neonatal functional epidermolysis bullosa. Br J Dermatol 1998; 138: 661-6.
8. Gatalica B, Pulkkinen L, Li K et al. Cloning of the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized atrophic benign epidermolysis bullosa. Am J Hum Genet 1997; 60: 352-65.
9. McGrath JA, McMillan JR, Dunnill MGS et al. Genetic basis of lethal junctional epidermolysis bullosa in an affected fetus: implications for prenatal diagnosis in one family. Prenatal Diagn 1995; 15: 647-54.
10. Mellerio JE, Dunnill MGS, Waridibe A et al. Recurrent mutations in the type VII collagen gene (COL7A1) in patients with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 1997; 109: 246-9.
11. Dunnill MGS, McGrath JA, Richards AJ et al. Clinicopathological correlations of compound heterozygous COL7A1 mutations in recessive dystrophic epidermolysis bullosa. J Invest Dermatol 1996; 107: 171-7.
12. Pas HH, Kloosterhuis GJ, Heeres K et al. Bullous pemphigoid and linear IgA dermatosis sera recognise a similar 120-kDa keratinocyte collagenous glycoprotein with antigenic cross-reactivity to BP180. J Invest Dermatol 1997; 108: 423-9.
13. Zone JJ, Taylor TB, Meyer LJ et al. The 97kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180kDa bullous pemphigoid antigen, BPAg2. J Invest Dermatol 1998; 110: 207-10.
14. Rusenko KW, Gammon WR, Briggaman RA. Type VII collagen is the antigen recognised by IgA anti-sublamina densa autoantibodies. J Invest Dermatol 1989; 92: 510 (Abstract).
15. Zambruno G, Manca V, Kanitakis J et al. Linear IgA bullous dermatosis with autoantibodies to a 290 kd antigen of anchoring fibrils. J Am Acad Dermatol 1994; 31: 884-8.
16. Hashimato T, Ishiko A, Shimizu H et al. A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies. Br J Dermatol 1996; 134: 316-9.
17. Allen J, Zhou S, Wakelin SH et al. Linear IgA disease: a report of two dermal binding sera which recognize a pepsin-sensitive epitope (?NC-1 domain) of collagen type VII. Br J Dermatol 1997; 137: 526-33.
18. Wakelin SH, Allen J, Zhou S et al. Drug-induced linear IgA disease with antibodies to collagen VII. Br J Dermatol 1998; 138: 310-14.
19. Chan LS, Vanderlugt CJ, Hashimoto T et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 1998; 110: 103-9.
20. Fine JD. Epidermolysis bullosa: variability of expression of cicatricial pemphigoid, bullous pemphigoid and epidermolysis bullosa acquisita antigens in clinically uninvolved skin. J Invest Dermatol 1985; 85: 47-9.
21. Shimizu H, Takizawa Y, Pulkkinen L et al. The 97 kDa linear IgA bullous dermatosis antigen is not expressed in a patient with generalised atrophic benign epidermolysis bullosa with a novel homozygous G258X mutation in COL17A1. J Invest Dermatol 1998; 111: 887-92.
22. Vodegal RM, Kiss M, De Jong MCJM et al. The use of skin substrates deficient in basement membrane molecules for the diagnosis of subepidermal autoimmune bullous disease. Eur J Dermatol 1998; 8: 83-5.
23. McIntosh I, Hamosh A, Dictz HC. Nonsense mutations and diminished mRXA levels. Nat Genet 1993; 4: 219.
24. McMillan JR, McGrath JA, Pulkkinen L et al. Immunohistochemical analysis of the skill in junctional epidermolysis bullosa using laminin 5 chain specific antibodies is of limited value in predicting the underlying gene mutation. Br J Dermatol 1997; 136: 817-22.
25. Ghohestani RF, Nicolas JF, Kanitakis J et al. Lincar IgA bullous dermatosis with IgA antibodies exclusively directed against the 180- or 230-kDa epidermal antigens. J Invest Dermatol 1997; 108: 854-8.